Total Payments
$13,609
2024 Payments
$1,023
Companies
36
Transactions
321
Medicare Patients
4,302
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$13,401 (98.5%)
Education$148.60 (1.1%)
Gifts$59.40 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,401 | 314 | 98.5% |
| Education | $148.60 | 6 | 1.1% |
| Gift | $59.40 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $5,558 | 107 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,235 | 24 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $891.07 | 37 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $741.19 | 6 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $617.73 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $453.99 | 21 | $0 (2018) |
| Merck Sharp & Dohme LLC | $443.73 | 7 | $0 (2024) |
| Amgen Inc. | $363.84 | 16 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $292.03 | 8 | $0 (2019) |
| Lilly USA, LLC | $241.77 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,023 | 30 | Novo Nordisk Inc ($295.08) |
| 2023 | $2,112 | 44 | Novo Nordisk Inc ($478.06) |
| 2022 | $1,586 | 22 | Novo Nordisk Inc ($764.06) |
| 2021 | $1,530 | 29 | Novo Nordisk Inc ($1,033) |
| 2020 | $621.23 | 10 | Novo Nordisk Inc ($298.24) |
| 2019 | $2,828 | 48 | Novo Nordisk Inc ($1,552) |
| 2018 | $1,997 | 70 | Novo Nordisk Inc ($498.79) |
| 2017 | $1,911 | 68 | Novo Nordisk Inc ($638.53) |
All Payment Transactions
321 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $31.77 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $37.73 | General |
| Category: Diabetes Care | ||||||
| 12/10/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $37.73 | General |
| Category: Diabetes Care | ||||||
| 11/12/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $36.59 | General |
| Category: Diabetes Care | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/25/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $33.06 | General |
| Category: Diabetes | ||||||
| 09/20/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: Diabetes | ||||||
| 09/05/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $28.73 | General |
| Category: Inflammation | ||||||
| 08/12/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Diabetes Care | ||||||
| 07/25/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/25/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Inflammation | ||||||
| 07/12/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Diabetes | ||||||
| 06/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: RESPIRATORY | ||||||
| 06/21/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $24.29 | General |
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/10/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: Inflammation | ||||||
| 05/21/2024 | Novo Nordisk Inc | Rivfloza (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Rare Disease | ||||||
| 05/20/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Cardiology | ||||||
| 05/10/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: Diabetes | ||||||
| 04/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/23/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: Diabetes | ||||||
| 03/15/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: Diabetes | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,305 | 3,584 | $730,673 | $333,312 |
| 2022 | 17 | 998 | 3,263 | $612,037 | $318,514 |
| 2021 | 20 | 1,025 | 3,346 | $510,221 | $331,886 |
| 2020 | 18 | 974 | 2,856 | $487,582 | $306,469 |
Total Patients
4,302
Total Services
13,049
Medicare Billing
$1.3M
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 124 | 514 | $100,321 | $48,970 | 48.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 28 | 209 | $107,579 | $40,944 | 38.1% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 133 | 589 | $89,854 | $38,061 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 131 | 353 | $80,367 | $37,597 | 46.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 19 | 119 | $71,742 | $37,584 | 52.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 113 | 546 | $41,542 | $26,999 | 65.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 42 | 264 | $45,196 | $18,729 | 41.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 183 | $29,410 | $13,961 | 47.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 80 | $35,430 | $12,463 | 35.2% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 43 | 55 | $18,321 | $8,778 | 47.9% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 32 | 32 | $20,800 | $8,028 | 38.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 55 | 55 | $13,221 | $8,026 | 60.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 56 | 86 | $16,750 | $8,024 | 47.9% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 52 | 52 | $15,600 | $6,003 | 38.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 53 | 74 | $11,340 | $5,258 | 46.4% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 52 | 72 | $5,700 | $2,957 | 51.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 28 | 38 | $6,333 | $2,810 | 44.4% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 48 | 48 | $3,840 | $1,542 | 40.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,816 | $1,490 | 39.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 26 | $3,051 | $1,376 | 45.1% |
| 11721 | Removal of fingernails or toenails, 6 or more nails | Office | 2023 | 13 | 30 | $3,000 | $1,069 | 35.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 30 | 31 | $2,170 | $905.82 | 41.7% |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 2023 | 13 | 13 | $1,498 | $730.56 | 48.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 40 | 41 | $1,662 | $521.36 | 31.4% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 11 | 12 | $1,097 | $251.58 | 22.9% |
About Dr. Christopher Adubor, MD
Dr. Christopher Adubor, MD is a Nephrology healthcare provider based in Mount Vernon, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962464594.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Adubor, MD has received a total of $13,609 in payments from pharmaceutical and medical device companies, with $1,023 received in 2024. These payments were reported across 321 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($13,401).
As a Medicare-enrolled provider, Adubor has provided services to 4,302 Medicare beneficiaries, totaling 13,049 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Mount Vernon, NY
- Active Since 04/06/2006
- Last Updated 12/02/2011
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1962464594
Products in Payments
- Ozempic (Drug) $2,742
- ENTRESTO (Drug) $866.62
- JARDIANCE (Drug) $759.55
- FARXIGA (Drug) $650.67
- Tresiba (Drug) $627.48
- Kerendia (Drug) $617.73
- RYBELSUS (Drug) $617.64
- ELIQUIS (Drug) $447.15
- Victoza (Drug) $390.93
- Rybelsus (Drug) $385.29
- XIFAXAN (Drug) $292.03
- ACTHAR (Biological) $266.25
- STEGLATRO (Drug) $248.79
- LOKELMA (Drug) $231.88
- MOUNJARO (Drug) $223.41
- AFREZZA (Drug) $214.43
- FASENRA (Drug) $192.97
- VERQUVO (Drug) $182.50
- UBRELVY (Drug) $175.04
- Parsabiv (Biological) $172.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Mount Vernon
Dr. Faisal Rashid, M.d, M.D
Nephrology — Payments: $1,030
Nephrology $1,030
Dr. Aileen Grace Cielo, M.d, M.D
Nephrology — Payments: $722.81
Nephrology $722.81
Dr. Matthew Novak, Md, MD
Nephrology — Payments: $717.21
Nephrology $717.21
Dr. Eugene De Guzman, M.d, M.D
Nephrology — Payments: $437.44
Nephrology $437.44
Mr. Parampreet Ghuman, Md, MD
Nephrology — Payments: $236.50
Nephrology $236.50
Dr. Steven Zelman, M.d, M.D
Nephrology — Payments: $150.23
Nephrology $150.23